Back to search
FDAFDA · Food and drugs·Recall number D-1152-2022

Clonidine Transdermal System, USP 0.3 mg/day, 4 Patches (NDC 51862-455-01) per Carton (51862-455-04), Rx only, Manufactured for: Mayne Pharma Greenville, NC 27834

Published June 29, 2022 · Recall initiated: June 9, 2022

Summary

FDA records drug Class II recall D-1152-2022, published June 29, 2022 and initiated June 9, 2022. Recalling firm: Mayne Pharma Inc; Status: Terminated; Reported quantity: 1440 cartons; Lot: Lot: 41179A Exp. Jan 2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Defective Delivery System: Out of specification for release liner removal force results at the 3-month CRT stability timepoint.

What to do

Voluntary: Firm initiated · Letter

Get an email if CLONIDINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CLONIDINE
Manufacturer
Mayne Pharma Inc
Distributor
Nationwide in the US Market
Lot
Lot: 41179A Exp. Jan 2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Clonidine Transdermal System, USP 0.3 mg/day, 4 Patches (NDC 51862-455-01) per Carton (51862-455-04), Rx only, Manufactured for: Mayne Pharma Greenville, NC 27834 recalled?

Yes. FDA published recall D-1152-2022 on June 29, 2022. Reported hazard: Defective Delivery System: Out of specification for release liner removal force results at the 3-month CRT stability timepoint.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CLONIDINE.